Mostrar el registro sencillo del ítem

dc.contributor.authorBatista Liz, J.C.
dc.contributor.authorGenre, F.
dc.contributor.authorPulito-Cueto, V.
dc.contributor.authorRemuzgo-Martínez, S.
dc.contributor.authorPrieto-Peña, D.
dc.contributor.authorMárquez, A.
dc.contributor.authorOrtego-Centeno, N.
dc.contributor.authorLeonardo, M.T.
dc.contributor.authorPeñalba, A.
dc.contributor.authorNarváez, J.
dc.contributor.authorMartín-Penagos, L.
dc.contributor.authorBelmar-Vega, L.
dc.contributor.authorGómez Fernández, Cristina
dc.contributor.authorMiranda Filloy, José Alberto 
dc.contributor.authorCaminal-Montero, L.
dc.contributor.authorCollado, P.
dc.contributor.authorDe Árgila, D.
dc.contributor.authorQuiroga-Colina, P.
dc.contributor.authorVicente-Rabaneda, E.F.
dc.contributor.authorTriguero-Martínez, A.
dc.contributor.authorRubio, E.
dc.contributor.authorLeón Luque, M.
dc.contributor.authorBlanco-Madrigal, J.M.
dc.contributor.authorGalíndez-Agirregoikoa, E.
dc.contributor.authorMartín, J.
dc.contributor.authorGualillo, Oreste
dc.contributor.authorBlanco, R.
dc.contributor.authorCastañeda, S.
dc.contributor.authorGonzález-Gay Mantecón, Miguel Ángel 
dc.contributor.authorLópez-Mejías, R.
dc.date.accessioned2025-08-26T11:19:25Z
dc.date.available2025-08-26T11:19:25Z
dc.date.issued2022
dc.identifier.citationBatista Liz JC, Genre F, Pulito-Cueto V, Remuzgo-Martínez S, Prieto-Peña D, Márquez A, et al. IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms. Journal of Clinical Medicine. 2022;11(19).
dc.identifier.issn2077-0383
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/6353fb8ef10b7f36130d5a0f*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20885
dc.description.abstractCD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV.en
dc.description.sponsorshipThis study was supported by European Union FEDER funds and Fondo de Investigaciones Sanitarias (grants PI18/00042 and PI21/00042) from Instituto de Salud Carlos III (ISCIII, Health Ministry, Spain). D.P.-P. is a recipient of a Rio Hortega program fellowship from the ISCIII, co-funded by the European Social Fund (ESF, Investing in your future) (grant number CM20/00006). F.G. is supported by funds of the RICORS Program from ISCIII, co-funded by the European Union (grant number RD21/0002/0025). V.P.-C. is supported by funds of PI18/00042. S.R.-M. is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). O.G. is a staff member of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (grant numbers RD16/0012/0014 (RIER) and PI17/00409). He is a beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Program, project 734899-Olive-Net. R.L.-M. is a recipient of a Miguel Servet type II program fellowship from the ISCIII, co-funded by ESF (Investing in your future) (grant number CPII21/00004).en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleIgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms*
dc.typeArticleen
dc.authorsophosBatista Liz, R. J. C.
dc.authorsophosGenre, F.
dc.authorsophosPulito-Cueto, V.
dc.authorsophosRemuzgo-Martínez, S.
dc.authorsophosPrieto-Peña, D.
dc.authorsophosMárquez, A.
dc.authorsophosOrtego-Centeno, N.
dc.authorsophosLeonardo, M. T.
dc.authorsophosPeñalba, A.
dc.authorsophosNarváez, J.
dc.authorsophosMartín-Penagos, L.
dc.authorsophosBelmar-Vega, L.
dc.authorsophosGómez-Fernández, C.
dc.authorsophosMiranda-Filloy, J. A.
dc.authorsophosCaminal-Montero, L.
dc.authorsophosCollado, P.
dc.authorsophosDe Árgila, D.
dc.authorsophosQuiroga-Colina, P.
dc.authorsophosVicente-Rabaneda, E. F.
dc.authorsophosTriguero-Martínez, A.
dc.authorsophosRubio, E.
dc.authorsophosLeón Luque, M.
dc.authorsophosBlanco-Madrigal, J. M.
dc.authorsophosGalíndez-Agirregoikoa, E.
dc.authorsophosMartín, J.
dc.authorsophosGualillo, O.
dc.authorsophosBlanco, R.
dc.authorsophosCastañeda, S.
dc.authorsophosGonzález-Gay, M. A.
dc.authorsophosLópez, Mejías
dc.identifier.doi10.3390/jcm11195577
dc.identifier.sophos6353fb8ef10b7f36130d5a0f
dc.issue.number19
dc.journal.titleJournal of Clinical Medicine*
dc.relation.projectIDEuropean Union FEDER funds; Instituto de Salud Carlos III (ISCIII, Health Ministry, Spain) [PI18/00042, PI21/00042]; ISCIII; European Social Fund (ESF, Investing in your future) [CM20/00006]; RICORS Program from ISCIII; European Union [RD21/0002/0025]; RETICS Program (ISCIII) [RD16/0012/0009]; RETICS Program (European Regional Development Fund (ERDF) [RD16/0012/0009]; European Union FEDER fund [RD16/0012/0014, PI17/00409]; Research Executive Agency (REA) of the European Union [734899]; Miguel Servet type II program fellowship from the ISCIII; ESF (Investing in your future) [CPII21/00004]
dc.relation.publisherversionhttps://www.mdpi.com/2077-0383/11/19/5577/pdf?version=1663904254;https://mdpi-res.com/d_attachment/jcm/jcm-11-05577/article_deploy/jcm-11-05577-v2.pdf?version=1663904254es
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Lugoes
dc.subject.keywordHULAes
dc.subject.keywordIDISes
dc.subject.keywordAS Santiagoes
dc.subject.keywordCHUSes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number11


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional